DexCom Historical Income Statement
DXCM Stock | USD 74.46 0.78 1.04% |
Historical analysis of DexCom income statement accounts such as Operating Income of 627.6 M or Ebit of 767.2 M can show how well DexCom Inc performed in making a profits. Evaluating DexCom income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of DexCom's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining DexCom Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DexCom Inc is a good buy for the upcoming year.
DexCom |
About DexCom Income Statement Analysis
DexCom Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to DexCom shareholders. The income statement also shows DexCom investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
DexCom Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of DexCom Inc. It is also known as DexCom overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from DexCom's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. At this time, DexCom's Net Income is very stable compared to the past year. As of the 22nd of November 2024, Income Tax Expense is likely to grow to about 177.3 M, while Interest Expense is likely to drop about 15.5 M.
DexCom income statement Correlations
Click cells to compare fundamentals
DexCom Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DexCom income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 60.3M | 84.7M | 102M | 18.6M | 20.3M | 15.5M | |
Other Operating Expenses | 1.3B | 1.6B | 2.2B | 2.5B | 3.0B | 3.2B | |
Operating Income | 142.3M | 299.5M | 175.4M | 391.2M | 597.7M | 627.6M | |
Ebit | 142.3M | 309.7M | 275.6M | 409.4M | 730.7M | 767.2M | |
Research Development | 273.5M | 359.9M | 604.2M | 484.2M | 505.8M | 531.1M | |
Ebitda | 164.5M | 376.8M | 377.5M | 565.3M | 916.7M | 962.5M | |
Total Operating Expenses | 789.2M | 980.6M | 1.4B | 1.5B | 1.7B | 1.8B | |
Net Income | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 568.6M | |
Income Tax Expense | 3.1M | (268.6M) | 19.2M | 49.6M | 168.9M | 177.3M | |
Depreciation And Amortization | 22.2M | 67.1M | 101.9M | 155.9M | 186M | 195.3M | |
Selling General Administrative | 482.6M | 544.2M | 684.1M | 867.2M | 1.0B | 1.1B | |
Income Before Tax | 104.2M | 225M | 173.9M | 390.8M | 710.4M | 745.9M | |
Total Other Income Expense Net | 80.1M | (38.1M) | (74.5M) | (9M) | 112.7M | 118.3M | |
Selling And Marketing Expenses | 33.1M | 76.5M | 126.4M | 133M | 180.8M | 189.8M | |
Total Revenue | 1.5B | 1.9B | 2.4B | 2.9B | 3.6B | 3.8B | |
Gross Profit | 931.5M | 1.3B | 1.7B | 1.9B | 2.3B | 2.4B | |
Cost Of Revenue | 544.5M | 646.6M | 768M | 1.0B | 1.3B | 1.4B | |
Net Income From Continuing Ops | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 568.6M | |
Net Income Applicable To Common Shares | 101.1M | 493.6M | 154.7M | 341.2M | 392.4M | 412.0M | |
Tax Provision | 3.1M | (268.6M) | 19.2M | 49.6M | 168.9M | 177.3M | |
Interest Income | 26.4M | 16.1M | 1.7M | 18M | 135M | 141.8M | |
Net Interest Income | (33.9M) | (68.6M) | (100.3M) | (18.6M) | 114.7M | 120.4M | |
Reconciled Depreciation | 48.7M | 67.1M | 102M | 155.9M | 186M | 95.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.